Product Description: Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Xichun Hu, et al. MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients. Journal of Clinical Oncology 38, no. 15_suppl.
CAS Number: 2460539-60-8
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: PD-1/PD-L1